$6 million Brain Canada grant awarded to McGill to develop virtual integrated patient platform
NMD4C are pleased to share that The Neuro has received a $6 million grant from Brain Canada to fund a new Open Science patient registry to share data with researchers around the world and let patients see how their data is used to develop new treatments for neurological disorders.
The Neuro’s Virtual Integrated Patient Platform (NeuroVIPs) will contain multi-modal data from thousands of patient partners stored across the institution’s various clinical and research platforms, including The Neuro’s Open Biobank. NeuroVIPs will create a digital link between these platforms, so that a patient’s phenotype, genetics, neuroimaging, and other data can be accessed by research teams in one centralized location.
Integrated neuromuscular biobank
We are excited to continue to work with The Neuro and C-BIG as the hub for our virtual neuromuscular biobank, and to apply their neuroinformatic architecture to the cataloging of Canadian neuromuscular tissue samples.
Learn more about the NeuroVIPs project
Read the full press releases from McGill University and Brain Canada to learn more!
Read next...
Important Deadlines for Ottawa NMD 2023
The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th!
European Neuromuscular Centre Mid-Career Mentoring Programme Now Open
The European Neuromuscular Centre (ENMC) Mid-Career Mentoring Programme is now open for the third round of mentee candidates!
CIHR Report: What we heard on the future of clinical trials
The Canadian Institute of Health Research (CIHR) have recently released an article outlining the results of their building the future of clinical trials consultation in a What We Heard report.
New Publication from NMD4C Investigators: Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond
A new study ‘Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond’ examines the differences between provincial newborn screening (NBS) programs and the variability of Spinal muscular atrophy (SMA) screening inclusion within these.
Muscular Dystrophy Canada fund nine new projects through 2023 grant program
Muscular Dystrophy Canada (MDC) recently announced the results of their ‘Neuromuscular Clinical and Translational Research Grant Program’, and we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting projects!
National strategy for drugs for rare disease update
Health Canada announced a new funding plan to support the first-ever national strategy for drugs for rare disease, with an investment of $1.5 billion over three years. This national strategy will increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada.